Clinical Trials on Chronic Obstructive Pulmonary Disease in Czechia

Total 848 results

AstraZeneca

Completed

A Trial Assessing LAS34273 in Moderate to Severe Stable Chronic Obstructive Pulmonary Disease (COPD)

Chronic Obstructive Pulmonary Disease (COPD)

Andorra, Austria, Belgium, Bulgaria, Czech Republic, Denmark, France, Germany, Hungary, Italy, Netherlands, Poland, Romania, Russian Federation, Spain, United Kingdom
Chiesi Farmaceutici S.p.A.

Recruiting

A 52-week, Placebo-controlled Study to Evaluate the Efficacy and Safety of 2 Doses of CHF6001 DPI (Tanimilast), as add-on to Maintenance Triple Therapy in Subjects With COPD and Chronic Bronchitis (PILASTER) (PILASTER)

Chronic Obstructive Pulmonary Disease

Bulgaria, United States, Albania, Argentina, Australia, Austria, Bosnia and Herzegovina, Chile, China, Czechia, Georgia, Germany, Greece, Hungary, Israel, Italy, Mexico, Netherlands, New Zealand, North Macedonia, Poland, Romania, Russian... and more
Novartis Pharmaceuticals

Completed

Safety and Efficacy of Indacaterol Once Daily Versus Salmeterol Twice Daily in Chronic Obstructive Pulmonary Disease (COPD) (INSIST)

Chronic Obstructive Pulmonary Disease (COPD)

United States, Germany, Spain, Turkey, Hungary, Czech Republic, India, Slovakia
GlaxoSmithKline

Completed

A Randomized Study, Comparing Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC /VI) Single Inhaler Triple Therapy, Versus Multiple Inhaler Therapy (Budesonide/Formoterol Plus Tiotropium) in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

Pulmonary Disease, Chronic Obstructive

United States, Germany, Czechia
Sanofi
Regeneron Pharmaceuticals

Recruiting

Study to Assess the Efficacy, Safety, and Tolerability of SAR440340/REGN3500/Itepekimab in Chronic Obstructive Pulmonary Disease (COPD) (AERIFY-2)

Chronic Obstructive Pulmonary Disease

Korea, Republic of, Turkey, United States, Chile, Czechia, Israel, Russian Federation, Argentina, Brazil, Bulgaria, Canada, Denmark, Estonia, France, Georgia, Germany, Hungary, India, Japan, Latvia, Lithuania, Mexico, Netherlands, Norway and more
GlaxoSmithKline

Completed

A Randomized Study, Comparing Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) Single Inhaler Triple Therapy, Versus Multiple Inhaler Therapy (Budesonide/Formoterol Plus Tiotropium) in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

Pulmonary Disease, Chronic Obstructive

Germany, United States, Netherlands, Czechia
Sanofi
Regeneron Pharmaceuticals

Active, not recruiting

Pivotal Study to Assess the Efficacy, Safety and Tolerability of Dupilumab in Patients With Moderate to Severe COPD With Type 2 Inflammation (NOTUS)

Chronic Obstructive Pulmonary Disease

Greece, Belgium, Spain, Argentina, Hungary, South Africa, United Kingdom, France, Latvia, Germany, Netherlands, Russian Federation, Ukraine, United States, Australia, Brazil, Bulgaria, Canada, Chile, Colombia, Czechia, Lithuania, Me... and more
Novartis Pharmaceuticals

Completed

QVA vs. Salmeterol/Fluticasone, 52-week Exacerbation Study, FLAME (EFfect of Indacaterol Glycopyronium Vs Fluticasone Salmeterol on COPD Exacerbations)

Chronic Obstructive Pulmonary Disease (COPD)

Germany, Colombia, India, Korea, Republic of, Poland, Romania, South Africa, Italy, Austria, Belgium, Croatia, Estonia, Hungary, Russian Federation, Taiwan, Turkey, Japan, Spain, Sweden, United Kingdom, China, Thailand, Canada, Hong Kong and more
GlaxoSmithKline

Completed

An Exercise Endurance Study to Evaluate the Effects of Treatment of Chronic Obstructive Pulmonary Disease (COPD) Patients With a Dual Bronchodilator: GSK573719/GW642444.Study B (COPD)

Pulmonary Disease, Chronic Obstructive

South Africa, United States, Canada, Ukraine, United Kingdom, Denmark, Czechia
Sanofi
Regeneron Pharmaceuticals

Completed

Pivotal Study to Assess the Efficacy, Safety and Tolerability of Dupilumab in Patients With Moderate-to-severe COPD With Type 2 Inflammation (BOREAS)

Chronic Obstructive Pulmonary Disease

Spain, Argentina, China, Mexico, Canada, Ukraine, Israel, Italy, Czechia, Korea, Republic of, Bulgaria, Chile, Denmark, Finland, Germany, Hungary, Japan, Poland, Romania, Russian Federation, Slovakia, Sweden, Turkey, United States
Janssen Research & Development, LLC

Completed

A Study to Evaluate the Effectiveness and Safety of CNTO6785 in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease

Pulmonary Disease, Chronic Obstructive

Poland, Germany, Taiwan, Malaysia, Korea, Republic of, Czech Republic, Russian Federation, Hungary
Chiesi Farmaceutici S.p.A.

Recruiting

A 52-week, Placebo- and Active- Controlled (Roflumilast, Daliresp® 500µg) Study to Evaluate the Efficacy and Safety of Two Doses of CHF6001 DPI (Tanimilast) as add-on to Maintenance Triple Therapy in Subjects With COPD and Chronic Bronchitis. (PILLAR) (PILLAR)

Chronic Obstructive Pulmonary Disease

Bulgaria, United States, Argentina, Austria, Bosnia and Herzegovina, Chile, Croatia, Czechia, Estonia, Germany, Greece, Hungary, Israel, Latvia, Mexico, Netherlands, New Zealand, North Macedonia, Poland, Romania, Russian Federation and more
GlaxoSmithKline

Completed

Study to Assess the Safety and PK of GSK573719 and GSK573719/GW642444(VI) Combination in Healthy Subjects and Subjects With Severe Renal Impairment

Pulmonary Disease, Chronic Obstructive

Czechia, Hungary
GlaxoSmithKline

Completed

A 12-week Study to Evaluate the Efficacy and Safety of Umeclidinium 62.5 Microgram (mcg) Compared With Glycopyrronium 44 mcg in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

Pulmonary Disease, Chronic Obstructive

Argentina, Germany, Romania, Russian Federation, Chile, Sweden, Spain, Hungary, Czechia, Norway
Novartis Pharmaceuticals

Completed

Exacerbation Study (INVIGORATE)

Chronic Obstructive Pulmonary Disease

Germany, Belgium, Colombia, Romania, South Africa, Italy, Hungary, Taiwan, Turkey, Switzerland, Australia, France, Israel, Sweden, China, Thailand, Estonia, Netherlands, Russian Federation, Slovakia, Spain, Argentina, Lithuania, Austria, Cana... and more
GlaxoSmithKline

Completed

A Comparison Study Between the Fixed Dose Triple Combination of Fluticasone Furoate/ Umeclidinium/ Vilanterol Trifenatate (FF/UMEC/VI) With Budesonide/Formoterol in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

Pulmonary Disease, Chronic Obstructive

Germany, Poland, Romania, Russian Federation, Ukraine, Bulgaria, Estonia, Mexico, Korea, Republic of, Slovakia, Greece, China, Italy, Hungary, Czechia
Pfizer

Completed

Study To Evaluate The Efficacy And Safety Of PH-797804 For 12 Weeks In Adults With Moderate To Severe Chronic Obstructive Pulmonary Disease (COPD) Taking Salmeterol Xinafoate/Fluticasone Propionate Combination

Pulmonary Disease, Chronic Obstructive

United States, Sweden, Australia, Hungary, Bulgaria, South Africa, Poland, Slovakia, India, Canada, Argentina, Czech Republic, Chile, New Zealand, United Kingdom
Pfizer

Completed

Study To Evaluate The Efficacy And Safety Of PH-797804 For 12 Weeks In Adults With Moderate To Severe Chronic Obstructive Pulmonary Disease (COPD) On A Background Of Tiotropium Bromide

Pulmonary Disease, Chronic Obstructive

United States, Hungary, Taiwan, South Africa, Germany, Bulgaria, Japan, Sweden, Poland, Slovakia, Argentina, Canada, Czech Republic, Spain
GlaxoSmithKline

Completed

Study to Compare the Addition of Umeclidinium Bromide (UMEC) to Fluticasone Furoate (FF)/Vilanterol (VI), With Placebo Plus FF/VI in Subjects With Chronic Obstructive Pulmonary Disease (COPD) -Study 2

Pulmonary Disease, Chronic Obstructive

Germany, United States, Korea, Republic of, Czech Republic
GlaxoSmithKline

Completed

Study to Evaluate the 24-Hour Pulmonary Function Profile of Fluticasone Furoate (FF) /GW642444 (Vilanterol) (VI) Inhalation Powder 100/25mcg Once Daily Compared With Fluticasone Propionate/Salmeterol Inhalation Powder 250/50mcg Twice Daily in Subjects With Chronic Obstructive Pulmonary Disease

Pulmonary Disease, Chronic Obstructive

Germany, Poland, Romania, United States, Czechia, Russian Federation
GlaxoSmithKline

Completed

A Study Comparing the Efficacy, Safety and Tolerability of Fixed Dose Combination (FDC) of FF/UMEC/VI With the FDC of FF/VI and UMEC/VI; Administered Once-daily Via a Dry Powder Inhaler (DPI) in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

Pulmonary Disease, Chronic Obstructive

Puerto Rico, United States, Australia, Argentina, France, Germany, Japan, Netherlands, Russian Federation, Spain, Ukraine, Finland, Czechia, Poland, Belgium, Chile, Peru, South Africa, Sweden, Thailand, Israel, Korea, Republic of, C... and more
Boehringer Ingelheim

Completed

Tiotropium + Olodaterol Fixed Dose Combination (FDC) in Chronic Obstructive Pulmonary Disease (OTEMTO 1)

Pulmonary Disease, Chronic Obstructive

United States, Belgium, Canada, Czech Republic, Denmark, Finland, Germany, South Africa, Spain, United Kingdom
Boehringer Ingelheim
Pfizer

Completed

Trial Comparing Tiotropium Inhalation Capsules vs Placebo in Chronic Obstructive Pulmonary Disease (COPD).

Pulmonary Disease, Chronic Obstructive

United States, Belgium, Canada, Czech Republic, Germany, Greece, Netherlands, Portugal, Ukraine, United Kingdom
GlaxoSmithKline

Completed

A Study to Evaluate the Efficacy and Safety of Umeclidinium Bromide/Vilanterol Compared With Fluticasone Propionate/Salmeterol Over 12 Weeks in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

Pulmonary Disease, Chronic Obstructive

Germany, Russian Federation, Spain, Netherlands, Hungary, Denmark, Poland, Czechia
Boehringer Ingelheim

Completed

Safety and Efficacy of BI 1744 CL in Patients With Chronic Obstructive Pulmonary Disease I

Pulmonary Disease, Chronic Obstructive

Argentina, Brazil, Canada, Croatia, Czech Republic, Denmark, Finland, Germany, Hong Kong, India, Italy, Korea, Republic of, Malaysia, Norway, Philippines, South Africa, Spain, Sweden, Thailand, Ukraine
GlaxoSmithKline

Completed

Survival Of Subjects With Chronic Obstructive Pulmonary Disease (COPD)

Pulmonary Disease, Chronic Obstructive

United States, Australia, France, Romania, Finland, Taiwan, Bulgaria, Estonia, Canada, Netherlands, Philippines, South Africa, Sweden, Spain, Singapore, Austria, Germany, Latvia, New Zealand, China, Ukraine, Thailand, Greece, United Kingdom and more
GlaxoSmithKline

Completed

Efficacy and Safety Study of Fluticasone Furoate (FF)/GW642444 Inhalation Powder and the Individual Components in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

Pulmonary Disease, Chronic Obstructive

United States, Germany, Japan, Romania, Russian Federation, Ukraine, Argentina, Poland, Czechia
Boehringer Ingelheim

Completed

Safety and Efficacy of BI 1744 CL in Patients With Chronic Obstructive Pulmonary Disease II

Pulmonary Disease, Chronic Obstructive

Argentina, Brazil, Canada, Czech Republic, Denmark, Finland, Germany, Hong Kong, India, Italy, Korea, Republic of, Malaysia, Norway, Philippines, Romania, Russian Federation, South Africa, Spain, Sweden, Thailand
GlaxoSmithKline

Completed

SERETIDE 50/500mcg Versus Tiotropium Bromide On Exacerbation Rates In Severe Chronic Obstructive Pulmonary Disease

Pulmonary Disease, Chronic Obstructive

Germany, Netherlands, Romania, Italy, Spain, Belgium, Denmark, Estonia, Sweden, Austria, Latvia, United Kingdom, Ukraine, Russian Federation, Greece, Czech Republic, Slovenia, Norway, Lithuania, Slovakia
Boehringer Ingelheim

Completed

Characterization of Lung Function Profile of Inhaled Tiotropium + Olodaterol Fixed Dose Combination Compared to Fluticasone Propionate + Salmeterol Fixed Dose Combination in COPD Patients

Pulmonary Disease, Chronic Obstructive

Belgium, Czech Republic, Denmark, Germany, Hungary, Netherlands, Spain, Sweden
Boehringer Ingelheim

Completed

Tiotropium+Olodaterol Fixed Dose Combination (FDC) Versus Tiotropium and Olodaterol in Chronic Obstructive Pulmonary Disease (COPD)

Pulmonary Disease, Chronic Obstructive

United States, Argentina, Australia, Bulgaria, Canada, China, Czech Republic, Denmark, Estonia, Finland, France, Germany, Guatemala, Hungary, India, Italy, Japan, Korea, Republic of, Mexico, Netherlands, New Zealand, Portugal, Russian... and more
Boehringer Ingelheim

Completed

Comparing the Efficacy of Tiotropium + Olodaterol (5/5 µg) Fixed Dose Combination (FDC) Over Tiotropium 5µg in Reducing Moderate to Severe Exacerbations in Patients With Severe to Very Severe Chronic Obstructive Pulmonary Disease.

Pulmonary Disease, Chronic Obstructive

United States, Argentina, Australia, Austria, Belgium, Brazil, Bulgaria, Canada, Chile, Colombia, Croatia, Czechia, Denmark, Finland, France, Germany, Greece, Guatemala, Hong Kong, Hungary, India, Ireland, Italy, Japan, Korea, Republic of, Latv... and more
GlaxoSmithKline

Completed

Study to Evaluate Efficacy and Safety of Mepolizumab for Frequently Exacerbating Chronic Obstructive Pulmonary Disease (COPD) Patients

Pulmonary Disease, Chronic Obstructive

United States, Australia, Canada, France, Poland, Russian Federation, Spain, Estonia, Belgium, Peru, Sweden, Greece, Mexico, Norway, Italy, Czechia
Pfizer

Terminated

Phase 2 Study of the Safety and Efficacy of UK-500,001 in Adult Patients With COPD

Pulmonary Disease, Chronic Obstructive

Australia, Canada, Czech Republic, Croatia, Spain, Hungary, Argentina, Singapore, United Kingdom, Chile
GlaxoSmithKline

Completed

Study to Evaluate the Effect of Fluticasone Furoate/Vilanterol on Survival in Subjects With Chronic Obstructive Pulmonary Disease

Pulmonary Disease, Chronic Obstructive

United States, Argentina, Japan, Poland, Romania, Russian Federation, Spain, Ukraine, Germany, Taiwan, Bulgaria, Hungary, France, Philippines, South Africa, Thailand, Israel, Korea, Republic of, Australia, Mexico, Slovakia, United... and more
Boehringer Ingelheim

Completed

A Study on the Control of Chronic Obstructive Pulmonary Disease (COPD) in Patients Taking the Combination of Tiotropium and Olodaterol Using the Respimat® Inhaler

Pulmonary Disease, Chronic Obstructive

Israel, Russian Federation, Ukraine, Bulgaria, Czechia, Hungary, Lithuania, Poland, Romania, Slovenia, Switzerland
GlaxoSmithKline

Completed

Evaluation of COPD (Chronic Obstructive Pulmonary Disease) to Longitudinally Identify Predictive Surrogate Endpoints (ECLIPSE)

Pulmonary Disease, Chronic Obstructive

United States, Canada, Ukraine, Spain, United Kingdom, New Zealand, Netherlands, Bulgaria, Norway, Denmark, Czech Republic, Slovenia
SciPharm SàRL

Completed

Efficacy and Tolerability of Subcutaneously Administered Treprostinil Sodium in Patients With Severe (Non-operable) Chronic Thromboembolic Pulmonary Hypertension (CTREPH) (CTREPH)

Non-operable Chronic Thromboembolic Pulmonary Hypertension

Austria, Poland, Czechia, Germany
GlaxoSmithKline

Completed

A 24-week Evaluation of GSK573719/Vilanterol (62.5/25mcg) and Components in COPD (DB2113373)

Pulmonary Disease, Chronic Obstructive

Japan, Russian Federation, Spain, United States, Bulgaria, Canada, Poland, South Africa, Thailand, Mexico, Chile, Greece, Czechia
Boehringer Ingelheim

Completed

Evaluation of the Long- Term Effects of Spiriva on Lung Function in COPD Patients

Pulmonary Disease, Chronic Obstructive

United States, Argentina, Australia, Austria, Belgium, Brazil, Czech Republic, Denmark, Finland, France, Germany, Greece, Hong Kong, Hungary, Ireland, Italy, Japan, Lithuania, Malaysia, Mexico, Netherlands, New Zealand, Norway, Philip... and more
GlaxoSmithKline

Completed

Study to Evaluate the 24-Hour Pulmonary Function Profile of Fluticasone Furoate/Vilanterol (FF/VI) Inhalation Powder 100/25mcg Once Daily Compared With Tiotropium Bromide Inhalation Powder 18mcg Once Daily in Subjects With COPD Who Have or Are At Risk for Co-morbid Cardiovascular Disease

Pulmonary Disease, Chronic Obstructive

United States, Canada, Germany, Romania, Poland, Czechia
Hoffmann-La Roche

Completed

TESRA: (Treatment of Emphysema With a Gamma-Selective Retinoid Agonist)

Emphysema

United States, South Africa, Hungary, Poland, Bulgaria, Latvia, Israel, Italy, Czech Republic, United Kingdom, Ukraine, Iceland
Pearl Therapeutics, Inc.

Completed

Study to Assess Efficacy and Safety of PT009 Compared to PT005, PT008, and Symbicort® Turbuhaler® on Lung Function Over 24-Weeks in Subjects With Moderate to Very Severe COPD (telos)

Chronic Obstructive Pulmonary Disorder

United States, Canada, Germany, Hungary, Korea, Republic of, Poland, Russian Federation, Czechia
St. Anne's University Hospital Brno, Czech Republic

Completed

Influence of Different Anesthetic Procedures on Sleep Disorder Breathing

Obstructive Sleep Apnea

Czechia
Novartis Pharmaceuticals

Completed

Study to Evaluate the Efficacy and Safety of Glycopyrronium or Indacaterol Maleate and Glycopyrronium Bromide Fixed-dose Combination Regarding Symptoms and Health Status in Patients With Moderate COPD Switching From Treatment With Any Standard COPD Regimen

COPD

Germany, Belgium, Poland, Romania, Italy, Spain, Estonia, Russian Federation, Austria, France, Slovakia, Czechia, Latvia, Lithuania, Greece, Hungary, United Kingdom, Portugal, Ireland, Norway, Slovenia, Denmark, Sweden
Novartis Pharmaceuticals

Completed

Dose-range Finding Efficacy and Safety Study for QBW251 in COPD Patients

Pulmonary Disease, Chronic Obstructive

Germany, United States, Belgium, Thailand, Australia, Netherlands, Slovakia, United Kingdom, France, Czechia, Korea, Republic of, Italy, Turkey, Argentina, Austria, Philippines, Hungary, Greece, Hong Kong, Canada, Spain, Denmark, Japan and more
Value Outcomes Ltd.
AstraZeneca

Completed

Characteristics of Type 2- High Inflammatory Endotype of Asthma Using New Biomarkers From Peripheral Blood and Exhaled Air and Its Effect on the Outcome of Therapy

Asthma, Bronchial | Bronchial Asthma | Asthma Chronic | Asthma; Eosinophilic

Czechia
St. Anne's University Hospital Brno, Czech Republic
Masaryk University

Recruiting

OSA as a Remote Ischemic Preconditioning in Vascular Surgery

Obstructive Sleep Apnea | Ischemia Reperfusion Injury | Vascular Aneurysm

Czechia
GlaxoSmithKline

Completed

Efficacy and Safety of the Addition of Fluticasone Propionate/Salmeterol (250/50mcg) Twice-daily to 2 Doses of Umeclidinium Bromide Inhalation Powder (62.5 or 125mcg) Once-daily Over 12 Weeks.

Pulmonary Disease, Chronic Obstructive

United States, Korea, Republic of, Chile, Poland, Czech Republic
Pfizer

Completed

A Study To Investigate The Safety, Toleration And Efficacy of PF00610355 In Chronic Obstructive Pulmonary Disease (COPD) Patients. (A7881013)

Lung Diseases | Lung Diseases, Obstructive | Pulmonary Disease, Chronic Obstructive

United States, Croatia, Hungary, Bulgaria, Poland, Slovakia, Germany, South Africa, Argentina, Turkey, Spain, Czechia

Clinical Trials on Chronic Obstructive Pulmonary Disease in Czechia

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Latvia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations